• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 8, 2017

View Archived Issues

Gene therapy firm Horama adds $22M in series B for ophthalmology program

LONDON – Horama SAS has closed a €19 million (US$22 million) series B round, providing the capital to start clinical development of its lead gene therapy program in the treatment of a rare inherited form of retinitis pigmentosa. Read More

Regulatory front

The FDA is seeking White House Office of Management and Budget approval to collect information in support of a new draft guidance to help drug sponsors prepare voluntary target product profiles (TPPs). Read More

In the clinic

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., started the phase III ENVISION trial testing givosiran, an RNAi therapeutic targeting aminolevulinic acid synthase 1, in approximately 75 patients with acute hepatic porphyrias, with a primary endpoint of annualized rate of porphyria attacks requiring hospitalization, urgent health care visit or hemin administration at home over the six-month treatment period. Read More

Appointments and advancements

Milestone Pharmaceuticals USA Inc., of Charlotte, N.C., part of Milestone Pharmaceuticals Inc., of Montreal, named Lorenz Muller chief commercial officer. Read More

Other news to note

Archerdx, of Boulder, Colo., said it signed an agreement to develop and commercialize a next-generation sequencing-based oncology companion diagnostic (CDx) for Summit, N.J.-based Celgene Corp.’s investigational drug, CC-122, for indications in diffuse large B-cell lymphoma (DLBCL). Read More

Financings

Invirsa Inc., of Columbus, Ohio, said it closed $520,000 in seed financing led by Cincytech with participation from Rev1 Ventures. Read More

TGA move to regulate autologous stem cell therapies is long overdue, industry says

PERTH, Australia – Companies in the regenerative medicine space have long been pushing the Therapeutic Goods Administration (TGA) to regulate autologous cell and tissue products in Australia, and they strongly support the agency’s moves toward stronger regulation. Read More

Oyster Point Pharma clamming up for now as $22M series A funds corneal surface bid

Oyster Point Pharmaceuticals Inc.’s $22 million series A financing will push two lead therapies in corneal surface disorders through phase II trials, but CEO Jeffrey Nau told BioWorld he was “not willing at the moment to comment on the mechanism of action. We want to make sure that we keep a competitive advantage for a little bit. Once we have our first clinical trial under our belt – and we’re very optimistic at the moment – we’ll share more information,” he said. Read More

Pique’s PT-107 extends median OS in phase II NSCLC trial

An allogeneic whole cell vaccine for the treatment of non-small-cell lung cancer (NSCLC) developed by Pique Therapeutics Inc. helped people with late-stage, second-line disease achieve a median overall survival (OS) of 12.5 months during a phase II trial, an improvement of 4.1 months over the median OS of patients who received placebo. For the 71 nonsquamous patients enrolled in the study, median OS extended to 15.5 months, besting median OS in the placebo arm by nearly 10 months. Read More

The virtues of virtualization

BERLIN – Outsourcing has been one of the megatrends that has swept over the pharmaceutical industry in recent decades. Manufacturing, research and commercialization have become virtualized to varying degrees as companies seek to minimize capital expenditure and maximize the return on their pipeline assets. Read More

Fosun’s Henlius closing in on China’s first biosimilar nod; HLX-01 under review

HONG KONG – With a series of advancements in the area of biosimilar development, China’s Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China. Read More

Focusing downstream may help untangle AD target woes

Treating aging rats with an experimental compound that prevented neuronal cell death protected the animals from both depressive symptoms that are often the first symptom of Alzheimer’s disease (AD), and the memory decline that follows. The compound did not, however, affect the amyloid beta (a-beta) plaques, tau phosphorylation and inflammation that are widely considered to be the toxic agents behind neuronal demise in AD. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe